🧬 PT-141 (Bremelanotide) – Research Overview
0. Category:
Sexual Health, Libido Enhancement, Neurological Modulation
1. Primary Research Use:
PT-141 is primarily researched for its potential to treat sexual dysfunction, including hypoactive sexual desire disorder (HSDD) in premenopausal women and erectile dysfunction (ED) in men. Unlike traditional ED medications that act on the vascular system, PT-141 operates through the central nervous system by activating melanocortin receptors, thereby influencing sexual arousal and desire.
2. Simple Analogy:
Imagine PT-141 as a “libido switch” in the brain. Instead of directing blood flow like other ED treatments, it stimulates the brain’s pathways responsible for sexual desire, effectively turning on the mental aspects of arousal.
3. What It Is (Chemical Summary):
PT-141, also known as Bremelanotide, is a synthetic peptide analog of α-melanocyte-stimulating hormone (α-MSH). It functions as a non-selective agonist of melanocortin receptors, particularly MC3 and MC4, which are involved in regulating sexual behavior.
4. Best Suited For:
Research involving PT-141 is best suited for:
- Investigating treatments for HSDD in premenopausal women.
- Exploring alternatives for ED in men, especially those unresponsive to phosphodiesterase type 5 inhibitors.
- Studying central nervous system pathways related to sexual arousal.
5. Not Recommended For / Caution In Research With:
Caution is advised when researching PT-141 in individuals with:
- Uncontrolled hypertension or cardiovascular diseases, due to potential increases in blood pressure.
- Pregnancy or breastfeeding, as safety data is limited.
- Known hypersensitivity to PT-141 or its components.
6. Synergistic Peptide Stacks:
PT-141 has been studied in combination with:
- Tadalafil (Cialis): To enhance erectile function through combined central and peripheral mechanisms.
- Testosterone Replacement Therapy: To address hormonal deficiencies contributing to sexual dysfunction.
7. Common Dosing Guidelines (Research Use):
| Experience Level | Common Dosage Range | Administration Timing |
|---|---|---|
| Beginner | 0.5 mg | 45 minutes before activity |
| Intermediate | 1.25 mg | 45 minutes before activity |
| Advanced | 1.75–2 mg | 45 minutes before activity |
Note: Administration is typically via subcutaneous injection.
8. Cycling Information:
Research protocols often recommend:
- Limiting use to no more than one dose within a 24-hour period.
- Not exceeding eight doses per month.
- Discontinuing use if no improvement is observed after eight weeks.
9. Similar Compounds & Comparison Chart:
| Compound | Mechanism of Action | Primary Use Cases | Notes |
|---|---|---|---|
| PT-141 | Melanocortin receptor agonist | HSDD, ED | Central nervous system action |
| Sildenafil | PDE5 inhibitor | ED | Vascular system action |
| Flibanserin | Serotonin receptor agonist | HSDD in premenopausal women | Daily oral administration |
10. Method of Administration:
PT-141 is administered via subcutaneous injection, typically in the abdomen or thigh, at least 45 minutes prior to anticipated sexual activity.
11. Regulatory Status (FDA Approval):
PT-141, under the brand name Vyleesi, is FDA-approved for the treatment of acquired, generalized HSDD in premenopausal women. It is not approved for use in men.
12. Legal Disclaimer:
All information provided is for educational and research purposes only. PT-141 should be used in compliance with applicable laws and regulations. It is essential to consult with appropriate regulatory bodies and ethics committees before initiating research involving this compound.
Reviews
There are no reviews yet.